Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms
- PMID: 34077939
- DOI: 10.1159/000517530
Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms
Abstract
Introduction: The overexpression of somatostatin receptor type 2 (SSTR2) is a unique characteristic of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), which establishes the basis for both diagnosis and therapy. The SSTR status can be evaluated by immunohistochemical staining (IHC) and 68Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) imaging. This study attempted to determine the relationship between IHC and 68Ga-DOTATATE PET/CT imaging and to explore the optimal cutoff value for SSTR IHC reading.
Patients and methods: A total of 100 GEP-NENs with SSTR PET/CT and pathological data were retrospectively analyzed, which consisted of neuroendocrine tumor (NET) G1 (n = 9), NET G2 (n = 64), NET G3 (n = 13), neuroendocrine carcinoma ( n = 10), and mixed neuroendocrine-non-NENs ( n = 4). SSTR2-IHC results were interpreted by 4 well-established semiquantitative scoring systems, including human epidermal growth factor receptor 2 (HER2) score, Volante score, H score, and immunoreactive score.
Results: In the homogeneous SSTR2 expression group (accounting for 57% of all cases), the 4 scoring systems were highly concordant with each other (Kendall's Tau-b coefficient range: 0.80-0.96, p < 0.001) and also highly correlated with the 68Ga-DOTATATE PET/CT imaging results (Spearman's rank correlation coefficients: 0.71, 0.86, 0.80, and 0.71, p < 0.001). In the heterogeneous group (43%), the 4 scoring systems revealed a lower level of concordance (the Kendall Tau-b coefficient range: 0.40-0.75, p < 0.01), and the correlation with 68Ga-DOTATATE PET/CT imaging was also lower, albeit statistically significant (Spearman's rank correlation coefficients: 0.53, 0.38, 0.36, and 0.33, p < 0.05). Heterogeneous SSTR2 expression was mainly observed in the HER2 2+ cases, for which the combination with H score could help identify positive cases with increased sensitivity and specificity. The highest sensitivity and specificity of H scores in predicting the imaging results were achieved at 86.10 and 89.30% when defining the cutoff value as 160, indicating that 80% of the tumor cells were moderately positive or 55% were strongly positive.
Conclusions: SSTR2 IHC was found to predict 68Ga-DOTATATE PET/CT imaging accurately, especially in the homogeneous expression group. According to the positive 68Ga-DOTATATE PET/CT outcomes, 80% of the tumor cells moderately positive or 55% strongly positive was the cutoff values for SSTR2-IHC reading.
Keywords: 68Ga-DOTATATE PET/CT imaging; Gastroenteropancreatic neuroendocrine neoplasms; Immunohistochemical scoring systems; Somatostatin receptor type 2.
© 2021 The Author(s). Published by S. Karger AG, Basel.
Similar articles
-
Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study.Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4182-4193. doi: 10.1007/s00259-022-05848-z. Epub 2022 Jun 8. Eur J Nucl Med Mol Imaging. 2022. PMID: 35674739 Free PMC article.
-
The Correlation Between [68Ga]DOTATATE PET/CT and Cell Proliferation in Patients With GEP-NENs.Mol Imaging Biol. 2019 Oct;21(5):984-990. doi: 10.1007/s11307-019-01328-3. Mol Imaging Biol. 2019. PMID: 30796708
-
Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.Nucl Med Commun. 2016 Oct;37(10):1030-7. doi: 10.1097/MNM.0000000000000547. Nucl Med Commun. 2016. PMID: 27243215
-
Gastroenteropancreatic Neuroendocrine Tumor Diagnosis: DOTATATE PET/CT.PET Clin. 2023 Apr;18(2):189-200. doi: 10.1016/j.cpet.2022.11.001. Epub 2022 Dec 28. PET Clin. 2023. PMID: 36585339 Review.
-
Diagnosis and Treatment of Lung Neuroendocrine Neoplasms: Somatostatin Receptor PET Imaging and Peptide Receptor Radionuclide Therapy.PET Clin. 2023 Apr;18(2):223-231. doi: 10.1016/j.cpet.2022.11.005. Epub 2022 Dec 28. PET Clin. 2023. PMID: 36585338 Review.
Cited by
-
DOTATATE PET Imaging in Olfactory Neuroblastoma and Association with SSTR Expression.J Neurol Surg B Skull Base. 2023 Jun 12;85(5):439-444. doi: 10.1055/a-2096-1802. eCollection 2024 Oct. J Neurol Surg B Skull Base. 2023. PMID: 39228885 Free PMC article.
-
Expression prevalence and dynamics of GPCR somatostatin receptors 2 and 3 as cancer biomarkers beyond NET: a paired immunohistochemistry approach.Sci Rep. 2023 Nov 27;13(1):20857. doi: 10.1038/s41598-023-47877-0. Sci Rep. 2023. PMID: 38012197 Free PMC article.
-
Comparing the Effect of Multiple Histone Deacetylase Inhibitors on SSTR2 Expression and [111In]In-DOTATATE Uptake in NET Cells.Cancers (Basel). 2021 Sep 29;13(19):4905. doi: 10.3390/cancers13194905. Cancers (Basel). 2021. PMID: 34638389 Free PMC article.
-
Comparison of radiolabeled somatostatin analogs (DOTATATE, DOTANOC, and DOTATOC) in somatostatin receptor (SSTR) imaging for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a narrative literature review.Ann Nucl Med. 2025 Aug;39(8):755-773. doi: 10.1007/s12149-025-02072-1. Epub 2025 Jun 28. Ann Nucl Med. 2025. PMID: 40580373 Review.
-
In Vivo Versus In Vitro Somatostatin Receptor Expression in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis of Correlation Studies.Int J Mol Sci. 2025 Jul 8;26(14):6551. doi: 10.3390/ijms26146551. Int J Mol Sci. 2025. PMID: 40724801 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous